Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
104
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Combination of 99mTc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study

Ping Li1 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China;2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China
,
Chang Liu4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Shuang Wu2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;7 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Lin Deng2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;8 Department of Radiology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China
,
Guangyuan Zhang2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;8 Department of Radiology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China
,
Xin Cai1 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China;2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China
,
Silong Hu4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Jingyi Cheng2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China;9 Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Xiaoping Xu4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9656-6233
ORCID Icon,
Bin Wu2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;10 Department of Radiology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Xiaomao Guo2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;7 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Yingjian Zhang4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Shen Fu5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;11 Department of Radiation Oncology, Shanghai Concord Cancer Hospital, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
&
Qing Zhang1 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China;2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 2191-2199 | Published online: 03 Mar 2021

References

  • Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–964. doi:10.1200/JCO.2006.09.781617350944
  • Nomiya T, Tsuji H, Kawamura H, et al. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: a report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiother Oncol. 2016;121:288–293. doi:10.1016/j.radonc.2016.10.00927836119
  • Habl G, Uhl M, Katayama S, et al. Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized Phase II study–the IPI trial. Int J Radiat Oncol Biol Phys. 2016;95:435–443. doi:10.1016/j.ijrobp.2016.02.02527084659
  • Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–1552. doi:10.2967/jnumed.117.19103128687599
  • Sawicki LM, Kirchner J, Buddensieck C, et al. Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46:1542–1550. doi:10.1007/s00259-019-04308-530879122
  • Qi WX, Zhang Q, Li P, et al. The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC). J Cancer Res Clin Oncol. 2016;142:1361–1367. doi:10.1007/s00432-016-2142-327008005
  • Hicks RM, Simko JP, Westphalen AC, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology. 2018;289:730–737. doi:10.1148/radiol.201818078830226456
  • Xu X, Zhang J, Hu S, et al. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nucl Med Biol. 2017;48:69–75. doi:10.1016/j.nucmedbio.2017.01.01028273495
  • Goffin KE, Joniau S, Tenke P, et al. Phase 2 Study of 99mTc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection. J Nucl Med. 2017;58:1408–1413. doi:10.2967/jnumed.116.18780728302763
  • Naik M, Reddy CA, Stephans KL, et al. Posttreatment prostate-specific antigen 6 months after radiation with androgen deprivation therapy predicts for distant metastasis-free survival and prostate cancer-specific mortality. Int J Radiat Oncol Biol Phys. 2016;96:617–623. doi:10.1016/j.ijrobp.2016.07.00927681757
  • Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–417. doi:10.1016/j.eururo.2019.01.04930773328
  • Caromile LA, Dortche K, Rahman MM, et al. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal. 2017;10(470):eaag3326. doi:10.1126/scisignal.aag332628292957
  • Ceci F, Herrmann K, Hadaschik B, et al. Therapy assessment in prostate cancer using choline and PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:78–83. doi:10.1007/s00259-017-3723-328540419
  • Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602–612. doi:10.1007/s00259-017-3887-x29185010
  • Schmidkonz C, Cordes M, Beck M, et al. Assessment of treatment response by 99mTc-MIP-1404 SPECT/CT: a pilot study in patients with metastatic prostate cancer. Clin Nucl Med. 2018;43:e250–e258. doi:10.1097/RLU.000000000000216229916921
  • Thomas L, Kantz S, Hung A, et al. 68Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost. Eur J Nucl Med Mol Imaging. 2018;45:1170–1178. doi:10.1007/s00259-018-3954-y29468311
  • Calais J, Czernin J, Cao M, et al. 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230–237. doi:10.2967/jnumed.117.20174929123013
  • Schmidkonz C, Goetz TI, Kuwert T, et al. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. Ann Nucl Med. 2019;33:891–898. doi:10.1007/s12149-019-01400-631502084
  • Wolf MB, Edler C, Tichy D, et al. Diffusion-weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique. J Magn Reson Imaging. 2017;46:850–860. doi:10.1002/jmri.2563528152251
  • Chen M, Zhang Q, Zhang C, et al. Combination of 68Ga-PSMA PET/CT and multiparameter MRI improves the detection of clinically significant prostate cancer: a lesion by lesion analysis. J Nucl Med. 2019;60:944–949. doi:10.2967/jnumed.118.22101030552201
  • Grubmüller B, Baltzer P, Hartenbach S, et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res. 2018;24:6300–6307. doi:10.1158/1078-0432.CCR-18-076830139879
  • Byun BH, Kong CB, Lim I, et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med. 2013;54:1053–1059. doi:10.2967/jnumed.112.11596423670899
  • Donati OF, Mazaheri Y, Afaq A, et al. Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology. 2014;271:143–152. doi:10.1148/radiol.1313097324475824

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.